Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arvinas Inc (NQ: ARVN )

32.82 +0.39 (+1.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 415,374
Open 33.80
Bid (Size) 32.12 (3)
Ask (Size) 33.80 (1)
Prev. Close 32.43
Today's Range 32.65 - 33.97
52wk Range 13.57 - 53.08
Shares Outstanding 68,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arvinas to Present at Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
From Arvinas Inc.
Via GlobeNewswire

Performance

YTD
-20.92%
-20.92%
1 Month
-13.40%
-13.40%
3 Month
-29.11%
-29.11%
6 Month
+93.86%
+93.86%
1 Year
+29.72%
+29.72%

More News

Read More
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Via Investor's Business Daily
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
From Arvinas Inc.
Via GlobeNewswire
Navigating 7 Analyst Ratings For Arvinas
Via Benzinga
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Arvinas: Q4 Earnings Insights
Via Benzinga
Arvinas Inc. (NASDAQ: ARVN) Climbs to New 52-Week High
Via Investor Brand Network
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Forecasting The Future: 6 Analyst Projections For Arvinas
Via Benzinga
Expert Outlook: Arvinas Through The Eyes Of 9 Analysts
Via Benzinga
Arvinas Announces Chief Financial Officer Transition
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
From Arvinas Inc.
Via GlobeNewswire
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
SPS Commerce Posts Upbeat Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
From Arvinas Inc.
Via GlobeNewswire
Eaton Posts Strong Results, Joins Ferrari, Boot Barn And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Arvinas Appoints Jared Freedberg as General Counsel
From Arvinas Inc.
Via GlobeNewswire
Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Torrid Reports Upbeat Results, Joins MBIA, Virco Mfg. And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.